Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 0 results

Early research (Phase 1)Looking for participantsNCT07553663
What this trial is testing

Evaluating the Pharmacokinetics and Safety of Miricorilant

Who this might be right for
Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD)+1 more
Corcept Therapeutics 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT07024212
What this trial is testing

Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

Who this might be right for
MASLD
Zhejiang Doer Biologics Co., Ltd. 110
Large-scale testing (Phase 3)Active Not RecruitingNCT06161571
What this trial is testing

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Who this might be right for
NASH/MASHNAFLD/MASLD
Akero Therapeutics, Inc 700